Condition: Advanced Solid Tumors · Metastatic Solid Tumors · Sponsor: Trutino Biosciences Inc.
This is a first-in-human, Phase I, multicenter, open-label, dose escalation study with dose expansion to evaluate the safety and antitumor activity of ODC-IL2 in patients with advanced or metastatic solid tumors. ODC-IL2 is a conditionally activated IL-2 prodrug and will be administered as a single agent via intravenous infusion on Days 1 and 15 of a 28-day cycle. Up to approximately 50 patients will be enrolled in this study.
This description comes directly from the study's public registry record.
Krystal Martinez · 602.358.8300 · kmartinez@td2inc.com
Krishna Patel · 602.358.8300 · kpatel@td2inc.com
Always discuss trial participation with your own doctor first.
| HonorHealth | Scottsdale, Arizona, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06770764